€12.2 0.4 3.0%
Last Trade - 9:44am
| Market Cap | ÂŁ263.3m |
| Enterprise Value | ÂŁ205.9m |
| Revenue | ÂŁ78.4k |
| Position in Universe | 397th / 847 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.21 | 0.091 | 0.091 | 2.50 | -34.6% | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Hyloris Pharmaceuticals is a Belgium-based specialty pharmaceutical company. Its focus is on re-engineering cardiovascular products. Additionally, it also further develops and improves already-approved pharmaceuticals and established products, creating new and different solutions. The Company’s diverse product-development portfolio spans a wide range of therapeutic indications and dosage forms.
| Last Annual | December 31st, 2019 |
| Last Interim | June 30th, 2020 |
| No. of Shareholders: | n/a |
| No. of Employees: | 10 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | Euronext - Brussels |
| Shares in Issue | 25,832,632 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | Boulevard Gustave Kleyer 17, LIEGE, 4000, Belgium |
| Web | https://hyloris.com/ |
| Phone | +32 4 3460207 |
| Contact | () |
| Auditors | KPMG Reviseurs d Entreprises SCc. |
As of 9:44am, shares in Hyloris Pharmaceuticals SA are trading at €12.2, giving the company a market capitalisation of £263.3m. This share price information is delayed by 15 minutes.
Shares in Hyloris Pharmaceuticals SA are currently trading at €12.2 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Hyloris Pharmaceuticals SA price has moved by % over the past year.
There are no analysts currently covering Hyloris Pharmaceuticals SA.
Hyloris Pharmaceuticals SA is scheduled to issue upcoming financial results on the following dates:
Hyloris Pharmaceuticals SA does not currently pay a dividend.
Hyloris Pharmaceuticals SA does not currently pay a dividend.
Hyloris Pharmaceuticals SA does not currently pay a dividend.
To buy shares in Hyloris Pharmaceuticals SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Hyloris Pharmaceuticals SA are currently trading at €12.2, giving the company a market capitalisation of £263.3m.
Here are the trading details for Hyloris Pharmaceuticals SA:
Based on an overall assessment of its quality, value and momentum, Hyloris Pharmaceuticals SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Hyloris Pharmaceuticals SA are currently priced at €12.2. At that level they are trading at 26.69% discount to the analyst consensus target price of 0.00.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hyloris Pharmaceuticals SA. Over the past six months, the relative strength of its shares against the market has been 17.59%. At the current price of €12.2, shares in Hyloris Pharmaceuticals SA are trading at 13.24% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Hyloris Pharmaceuticals SA.
We were unable to find the directors for Hyloris Pharmaceuticals SA.
Here are the top five shareholders of Hyloris Pharmaceuticals SA based on the size of their shareholding:
